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Abstract We recently identified 1K,25-dihydroxy-3-epi-vitamin
D3 as a major in vitro metabolite of 1K,25-dihydroxyvitamin D3,
produced in primary cultures of neonatal human keratinocytes.
We now report the isolation of 1K,25-dihydroxy-3-epi-vitamin
D3 from the serum of rats treated with pharmacological doses of
1K,25-dihydroxyvitamin D3. 1K,25-dihydroxy-3-epi-vitamin D3
was identified through its co-migration with synthetic 1K,25-
dihydroxy-3-epi-vitamin D3 on both straight and reverse phase
high performance liquid chromatography systems and by mass
spectrometry. Along with 1K,25-dihydroxy-3-epi-vitamin D3,
other previously known metabolites, namely, 1K,24(R),25-
trihydroxyvitamin D3, 1K,25-dihydroxy-24-oxo-vitamin D3 and
1K,25-dihydroxyvitamin D3-26,23-lactone, were also identified.
Thus, our study for the first time provides direct evidence to
indicate that 1K,25-dihydroxy-3-epi-vitamin D3 is an in vivo
metabolite of 1K,25-dihydroxyvitamin D3 in rats.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
It is now well established that the secosteroid hormone,
1K,25-dihydroxyvitamin D3 (1K,25(OH)2D3) is metabolized
in its various target tissues, such as the kidney [1,2], intestine
[3^5], keratinocytes [6,7], bone [8^14] and cartilage [8,16],
through both C-24 and C-23 oxidation pathways. The C-24
oxidation pathway, initiated by C-24 hydroxylation, leads to
the conversion of 1K,25(OH)2D3 into calcitroic acid [2,17],
while the C-23 oxidation pathway, initiated by C-23 hydrox-
ylation, leads to the conversion of 1K,25(OH)2D3 into calci-
triol lactone [1,4,18,19]. It is now well accepted that the C-24
oxidation pathway plays an important role in the ¢nal inacti-
vation of the hormone in its various target tissues [17]. The
signi¢cance of the C-23 oxidation pathway remains to be
elucidated. Recently, the production of 1K,25-dihydroxy-3-
epi-vitamin D3 (1K,25(OH)2-3-epi-D3), through the C-3 epi-
merization pathway as a novel metabolite of 1K,25(OH)2D3,
was identi¢ed in human keratinocytes incubated with both
pharmacological and physiological concentrations of
1K,25(OH)2D3 [20,21].
Even though 1K,25(OH)2-3-epi-D3 was identi¢ed as one of
the major in vitro metabolites of 1K,25(OH)2D3, it still re-
mains to be determined whether this novel in vitro metabolite
is also a circulating metabolite in intact animals. Therefore, in
our present study, we investigated the in vivo metabolism of
1K,25(OH)2D3 in rats. We successfully isolated a metabolite
less polar than 1K,25(OH)2D3 in the pure form from the se-
rum of rats treated with pharmacological doses of
1K,25(OH)2D3. This metabolite exhibited chromatographic
and mass spectral properties identical to the synthetic stand-
ard of 1K,25(OH)2-3-epi-D3. Thus, for the ¢rst time, we pro-
vide evidence indicating that 1K,25(OH)2-3-epi-D3 is one of
the in vivo metabolites of 1K,25(OH)2D3, detectable in rats
treated with pharmacological doses of 1K,25(OH)2D3, and
that the C-3 epimerization pathway is operative in vivo.
2. Materials and methods
2.1. Vitamin D compounds
Synthetic standards of 1K,25(OH)2D3, 1K,25(OH)2-3-epi-D3,
1K,24(R),25-trihydroxyvitamin D3 (1K,24(R),25(OH)3D3) and 1K,25-
dihydroxyvitamin D3-26,23-lactone (1K,25(OH)2D3-lactone) were syn-
thesized at Ho¡mann-La Roche (Nutley, NJ, USA). 1L,25(OH)2D3
and 1L,25(OH)2-3-epi-D3 were synthesized using the procedure de-
scribed previously [22]. The authentic standard of 1K,25-dihydroxy-
24-oxo-vitamin D3 (1K,25(OH)2-24-oxo-D3) was produced enzymati-
cally using the isolated rat kidney perfusion system as described be-
fore [2]. All the vitamin D3 compounds were quanti¢ed by UV spec-
troscopic analysis assuming an extinction coe⁄cient (V265 nm) of
18 300 dm3/mol/cm. 1K,25(OH)2D3 was dissolved in ethanol and in-
jected in vehicle consisting of 50% normal rat serum in a saline solu-
tion.
2.2. Rats
Male Sprague-Dawley rats (Taconic Laboratories, Germantown,
NY, USA), weighing approximately 350 g, were used in all experi-
ments, following adaptation to laboratory conditions for at least
5 days. They were housed two per cage with free access to food
and water in a regulated environment, with a 12 h light-dark cycle.
2.3. In vivo metabolism of 1K,25(OH)2D3 in rats
In vivo metabolism studies were performed using two protocols.
The ¢rst protocol was designed to ¢nd out the right time point to
kill the rats in order to obtain the best information about the various
circulating metabolites of 1K,25(OH)2D3. In this protocol, four rats
were used. Each rat was given a bolus dose of 500 Wg of
1K,25(OH)2D3 intravenously. The rats were killed at di¡erent time
points (1, 2, 4 and 8 h) following the bolus dose. The blood was
collected from each rat by catheterization of the aorta. The blood
samples were immediately centrifuged to obtain 5^7 ml of serum
from each rat. Based on the information obtained from the analysis
of the metabolism data of the ¢rst protocol, the second protocol was
designed. In this protocol, ¢ve rats were used. One rat was treated
with vehicle solution alone, as the control. Each of the remaining four
FEBS 21845 2-4-99
0014-5793/99/$20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 0 3 7 7 - 4
*Corresponding author. Fax: (1) (401) 276 7810.
FEBS 21845FEBS Letters 448 (1999) 278^282
rats received respectively, a single bolus dose of 50, 100, 250 or 500 Wg
of 1K,25(OH)2D3 intravenously. 4 h after dosing, each rat was killed
and the blood, collected by catheterization of the aorta, was centri-
fuged immediately. About 5^7 ml of serum was obtained from each
rat and the serum was stored at 320‡C for future analysis.
2.4. Lipid extraction
Lipid extraction of serum was initiated by ¢rst adding two volumes
of methanol to each serum sample. The protein precipitate was sep-
arated from the supernatant by centrifuging at 3000 rpm in a refri-
gerated centrifuge at 4‡C for 15 min. The supernatant was mixed with
four volumes of dichloromethane in a separatory funnel. The lower
organic phase was collected and dried at 50‡C under nitrogen gas.
After reconstitution in 10% isopropanol/hexane, the lipid extract was
directly subjected to analysis by high performance liquid chromatog-
raphy (HPLC). In these experiments, we performed the lipid extrac-
tion of serum samples without an internal standard and therefore, the
results should be considered semi-quantitative. However, in a separate
experiment, we calculated the recovery of extraction of 1K,25(OH)2D3
from rat serum. The extraction e⁄ciency was 74.6 þ 0.7% (mean þ
S.D., n = 5), with an intra assay coe⁄cient of variation of 1.0%. These
results indicate that the e⁄ciency of our lipid extraction procedure
should not change signi¢cantly from sample to sample.
2.5. HPLC
HPLC analysis was performed with a Waters system controller
(Millennium 32) equipped with a photodiode array detector (Model
PDA 996) to monitor the UV absorption at 265 nm. A Zorbax SIL
9.4U250 mm column (Dupont, Wilmington, DE, USA) was used for
all straight phase systems and a Zorbax ODS 4.6U250 mm column
(Dupont, Wilmington, DE, USA) was used for the reverse phase
system.
2.6. Isolation and identi¢cation of various metabolites of
1K,25(OH)2D3 from rat serum
The initial identi¢cation and quanti¢cation of all the in vivo me-
tabolites were performed using the straight phase HPLC system I
consisting of a Zorbax-SIL column eluted with 10% isopropanol/hex-
ane at a £ow rate of 2 ml/min. The data shown in Table 1 and Figs. 1
and 2 were generated using only the HPLC system I. For the ¢nal
identi¢cation of the metabolites, the total HPLC eluates obtained
from the analysis of all the individual serum samples were pooled
together and re-subjected to the same straight phase HPLC system
I. The HPLC fractions 20^28 min, 38^44 min and 51^62 min contain-
ing the putative 1K,25(OH)2-3-epi-D3 (retention time (R.T.) 22.7 min),
1K,24(R),25(OH)3D3 (R.T. 42.9 min) and 1K,25(OH)2D3-lactone
(R.T. 59.3 min), respectively, were collected manually. In order to
separate the 1K,25(OH)2-3-epi-D3 metabolite from the contaminant
J1 and the substrate, fraction 20^28 min was further analyzed using
a straight phase HPLC system consisting of 6% isopropanol/hexane at
a £ow rate of 2 ml/min (HPLC system II). The 1K,25(OH)2-3-epi-D3
metabolite was further puri¢ed on a reverse phase HPLC system using
20% water/methanol at a £ow rate of 1 ml/min (HPLC system III).
After puri¢cation, the putative 1K,25(OH)2-3-epi-D3 was identi¢ed by
its co-elution with the synthetic standard of 1K,25(OH)2-3-epi-D3 us-
ing two di¡erent HPLC systems (HPLC systems I and III), (Table 2).
The putative 1K,24(R),25(OH)3D3 was identi¢ed by its co-elution with
the synthetic standard of 1K,24(R),25(OH)3D3 on a straight phase
HPLC system using 6% isopropanol/dichloromethane at a £ow rate
of 2 ml/min (HPLC system IV). The putative 1K,25(OH)2D3-lactone
was identi¢ed by its co-elution with the synthetic standard of
1K,25(OH)2D3-lactone on a straight phase HPLC system using 10%
isopropanol/dichloromethane at a £ow rate of 2 ml/min (HPLC sys-
tem V). The ¢nal amounts of all the metabolites obtained in pure
form for gas chromatography/mass spectrometry (GC/MS) analysis
from 70 ml of serum are as follows: 1K,25(OH)2-3-epi-D3, 1 Wg;
1K,24(R),25(OH)3D3, 2 Wg and 1K,25(OH)2D3-lactone, 4 Wg.
2.7. GC/MS
Identi¢cation of all the metabolites of 1K,25(OH)2D3 was per-
formed using a Hewlett-Packard GC-MSD system, composed of a
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Table 1
The serum concentration of 1K,25(OH)2D3 and its metabolites following a single intravenous dose (500 Wg) of 1K,25(OH)2D3, given to various
rats, killed at di¡erent time points
Concentration (ng/ml)
1 h 2 h 4 h 8 h
1K,25(OH)2D3 2232 1975 1745 515
1K,25(OH)2-3-epi-D3 10 18 34 15
1K,24(R),25(OH)3D3 12 34 152 48
1K,25(OH)2-24-oxo-D3 9 10 33 8
1K,25(OH)2D3-lactone ND 17 120 143
ND, not detectable.
Fig. 1. The HPLC pro¢le of various metabolites of 1K,25(OH)2D3
in rat serum. I: HPLC pro¢le of synthetic standards of vitamin D3.
II : HPLC pro¢le and UV spectra of the vitamin D3 metabolites in
the lipid extract of 7 ml of serum obtained from a rat which re-
ceived 500 Wg of 1K,25(OH)2D3 intravenous, 4 h prior to be killed.
III: HPLC pro¢le and UV spectra of the lipid contaminants in 7 ml
serum obtained from the control rat, treated with only vehicle solu-
tion intravenous, 4 h prior to be killed. HPLC was performed using
a Zorbax-SIL column (9.4U250 mm) eluted with 10% isopropanol/
hexane at a £ow rate of 2 ml/min.
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5890 series II chromatograph, a 5971 mass selective detector and a
7673 GC autosampler. Synthetic standards and metabolites of
1K,25(OH)2D3 were dried down under nitrogen, reconstituted in
15 Wl of acetonitrile and trimethylsilylated by the addition of 15 Wl
of Power SIL-Prep (Alltech Associates, Deer¢eld, IL, USA). The
samples were incubated at 70‡C for 15 min to ensure the complete
derivatization. Derivatives were then transferred to autosampler vials
and analyzed on a HP-5 capillary column (30 mU0.25 mmU0.25 mm,
5% phenyl methyl silicone), using UHP helium as a carrier gas. The
oven temperature program was as follows: 150‡C for 6 min, then
increasing at 10‡C/min until reaching a ¢nal temperature of 300‡C
which was held for 10 min. Full scan spectra were acquired over a
mass range of m/z 50^650 and published spectra were averaged and
background-subtracted.
3. Results
3.1. In vivo metabolites of 1K,25(OH)2D3 in rats
Fig. 1I illustrates the chromatographic pro¢le of the not
metabolized 1K,25(OH)2D3 (peak S) and four of its metabo-
lites detected in 7 ml of serum obtained from a rat treated
with 500 Wg of 1K,25(OH)2D3. All of the four metabolites
possessed the characteristic vitamin D cis-triene chromophore
and the initial identi¢cation of each metabolite was achieved
by HPLC via co-chromatography with known authentic
standards (Fig. 1.II). The less polar metabolite eluting
before the substrate (peak A) was identi¢ed as the putative
1K,25(OH)2-3-epi-D3, which had been previously observed in
in vitro studies [3,7,15,20,24,25]. The more polar metab-
olites were identi¢ed as 1K,25(OH)2-24-oxo-D3 (peak B),
1K,24(R),25(OH)3D3 (peak C) and 1K,25(OH)2D3-lactone
(peak D). None of the metabolites of 1K,25(OH)2D3 were
detected in 7 ml of the serum from the rat treated with vehicle
alone (Fig. 1.III). The serum from the control rat contained
only peaks J1 and J2, which were considered to be contami-
nants based on their UV spectra. The contaminants did not
exhibit the UV spectral characteristics which are typical to a
vitamin D cis-triene chromophore. The ¢nal identi¢cation of
all the afore-mentioned metabolites, with the exception of
1K,25(OH)2-24-oxo-D3, was obtained through GC/MS as de-
scribed later. The results of the time course study are pre-
sented in Table 1. At 1 h, only 1K,25(OH)2-3-epi-D3,
1K,24(R),25(OH)3D3 and 1K,25(OH)2-24-oxo-D3 could be de-
tected in the serum. The concentration of these metabolites
reached a maximum at 4 h and started to decrease at 8 h. On
the contrary, 1K,25(OH)2D3-lactone was detected at 2 h after
dosing and its concentration was the highest at 8 h.
The results of the dose-response study are summarized in
Fig. 2. The concentration of unmetabolized substrate,
1K,25(OH)2D3 (S) and the concentration of the metab-
olites 1K,25(OH)2-3-epi-D3 (A), 1K,24(R),25(OH)3D3 (C),
1K,25(OH)2-24-oxo-D3 (B) and 1K,25(OH)2D3-lactone (D),
detected in the rats dosed with 100, 250 and 500 Wg, are
illustrated in II, III and IV, respectively. None of the above
metabolites were detected by HPLC in the rat treated with
50 Wg of 1K,25(OH)2D3 (Fig. 2.I). The concentration of
1K,25(OH)2-3-epi-D3 increased in a dose-dependent manner,
as did the metabolites derived from the C-24 and
C-23 oxidation pathways. At all doses, the relative con-
centrations of the metabolites at 4 h were as follows:
1K,25(OH)2D3-lactones 1K,24(R),25(OH)3D3s 1K,25(OH)2-
3-epi-D3s 1K,25(OH)2-24-oxo-D3.
3.2. Final identi¢cation of the in vivo metabolites of
1K,25(OH)2D3
All the metabolites isolated from the serum were puri¢ed
using the various HPLC systems described in Section 2. The
initial identi¢cation of the previously known metabolites
(1K,24(R),25(OH)3D3, 1K,25(OH)2-24-oxo-D3 and 1K,25-
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Table 2
Retention times of 1K,25(OH)2D3, its three diastereomers and peak A
A-ring hydroxy orientation Retention time (min)
Straight phase HPLC Reverse phase HPLC
1K,25(OH)2D3 1K, 3L 24.91 24.78
1L,25(OH)2-3-epi-D3 1L, 3K 25.01 24.88
1L,25(OH)2-D3 1L, 3L 22.87 26.49
1K,25(OH)2-3-epi-D3 1K, 3K 22.50 24.49
Peak A 22.57 24.26
Fig. 2. The serum concentration of 1K,25(OH)2D3 and its metabo-
lites in rats, 4 h after intravenous treatment with 50 Wg (I), 100 Wg
(II), 250 Wg (III) and 500 Wg (IV) of 1K,25(OH)2D3. The amounts
of 1K,25(OH)2D3 and its metabolites were quantitated using the
HPLC system described in Fig. 1.
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(OH)2D3-lactone) was achieved through their co-chromatog-
raphy with the known synthetic standards on two di¡erent
HPLC systems. The ¢nal identi¢cation of two of the metab-
olites (1K,24(R),25(OH)3D3 and 1K,25(OH)2D3-lactone) was
also achieved by GC/MS (data not shown). The initial iden-
ti¢cation of the new metabolite obtained in pure form from
peak A (putative 1K,25(OH)2-3-epi-D3) was achieved ¢rst
through its co-chromatography with synthetic 1K,25(OH)2-3-
epi-D3 on both straight and reverse phase HPLC systems. The
retention times of peak A, the synthetic standards of
1K,25(OH)2D3 and its three diastereomers on both straight
and reverse phase HPLC systems are given in Table 2. The
¢nal identi¢cation of peak A as 1K,25(OH)2-3-epi-D3 was
achieved through GC/MS. GC/MS analysis of the trimethyl-
silylated standard, 1K,25(OH)2-3-epi-D3, yielded a major
chromatographic peak at 25.32 min. The resulting mass spec-
trum, shown in Fig. 3I, exhibits many of the ion fragments
typical to the dihydroxylated vitamin D3 side-chain. By com-
parison, the trimethylsilyl derivative of 1K,25(OH)2D3 (the
1K,3L-diastereomer) elutes at a retention time of 23.94 min
(data not shown) and exhibits noticeably lower relative inten-
sities for the m/z 217 and m/z 501 ion fragments. Analysis of
peak A, isolated from rat serum, yielded a retention time of
25.31 min and a mass spectrum (Fig. 3.II) which is e¡ectively
identical to that of 1K,25(OH)2-3-epi-D3 (Fig. 3.I). Thus,
based on both the GC retention time data and the mass spec-
tral analysis, the identity of the metabolite in peak A isolated
from rat serum is unequivocally con¢rmed as 1K,25(OH)2-3-
epi-D3.
4. Discussion
The identi¢cation of 1K,25(OH)2-3-epi-D3 as a novel in
vitro metabolite of 1K,25(OH)2D3 produced in primary cul-
tures of human keratinocytes [20] led us to perform the
present study. In rats treated with 100^500 Wg of
1K,25(OH)2D3, we detected a metabolite which is less polar
than 1K,25(OH)2D3 on a straight phase HPLC system. The
metabolite co-migrated with the synthetic standard of
1K,25(OH)2-3-epi-D3 on both straight and reverse phase
HPLC systems and its ¢nal unequivocal identi¢cation was
achieved by GC/MS. The concentration of 1K,25(OH)2-3-
epi-D3 increased in a dose-dependent manner. Along with
1K,25(OH)2-3-epi-D3, we also isolated from the serum other
previously known metabolites, namely, 1K,24(R),25(OH)3D3,
1K,25(OH)2-24-oxo-D3 and 1K,25(OH)2D3-lactone. Earlier, in
vivo studies by Ishizuka et al. [23] in dogs treated with a total
of 3 mg of 1K,25(OH)2D3, also identi¢ed 1K,24(R),
25(OH)3D3, 1K,25(OH)2-24-oxo-D3 and 1K,25(OH)2D3-lac-
tone as the circulating metabolites of 1K,25(OH)2D3. Our
time course study results showed that the 1K,25(OH)2-3-epi-
D3 production reached a maximum at 4 h and decreased at 8
h, suggesting that 1K,25(OH)2-3-epi-D3 was further metabo-
lized. Results from kidney perfusion experiments with
1K,25(OH)2-3-epi-D3 revealed that 1K,25(OH)2-3-epi-D3 is
also metabolized through the C-24 oxidation pathway
(Reddy, G.S. et al., unpublished observation), which would
account for the decrease in 1K,25(OH)2-3-epi-D3 concentra-
tion at 8 h.
Since the discovery of 1K,25(OH)2-3-epi-D3 as a major me-
tabolite of 1K,25(OH)2D3 in primary cultures of keratinocytes
[20], the in vitro production of 1K,25(OH)2-3-epi-D3 was also
con¢rmed in several cell lines such as human colon adenocar-
cinoma cells (Caco-2 cells) [3], rat osteosarcoma cells (UMR
106 and Ros 17/2.8) [24,25] and primary cultures of bovine
parathyroid cells [15]. Siu-Caldera, M.-L. et al. also observed
that 1K,25(OH)2-3-epi-D3 was produced in ROS 17/2.8 cells
which do not possess the C-24 oxidation pathway [26]. Thus,
it appears that the metabolism of 1K,25(OH)2D3 into
1K,25(OH)2-3-epi-D3 can also occur in some tissues in which
the C-24 oxidation pathway is absent. It is reported that the
genomic activities (intestinal calcium transport and bone cal-
cium mobilization) of 1K,25(OH)2-3-epi-D3 when compared
to 1K,25(OH)2D3 are signi¢cantly reduced. Furthermore, the
binding a⁄nity of 1K,25(OH)2-3-epi-D3 to the vitamin D re-
ceptor is only 24% of that of 1K,25(OH)2D3 [25]. Therefore,
the C-3 epimerization pathway, like the previously well estab-
lished C-24 oxidation pathway, appears to play an important
role in inactivating 1K,25(OH)2D3. Furthermore, C-3 epime-
rization might even become the alternate pathway for the
inactivation of 1K,25(OH)2D3 in vitamin D target tissues, es-
pecially in which the C-24 oxidation pathway is absent.
In summary, the results of our study indicate for the ¢rst
time that 1K,25(OH)2-3-epi-D3 is a circulating metabolite of
1K,25(OH)2D3 in rats treated with pharmacological doses of
1K,25(OH)2D3 and that the C-3 epimerization pathway is op-
erative in vivo. The formation of 1K,25(OH)2-3-epi-D3 in
these rats may play an important role in reducing the toxicity
of 1K,25(OH)2D3.
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